PL2581387T3 - Przeciwciało monoklonalne anty-Tat HIV-1 - Google Patents

Przeciwciało monoklonalne anty-Tat HIV-1

Info

Publication number
PL2581387T3
PL2581387T3 PL11306314T PL11306314T PL2581387T3 PL 2581387 T3 PL2581387 T3 PL 2581387T3 PL 11306314 T PL11306314 T PL 11306314T PL 11306314 T PL11306314 T PL 11306314T PL 2581387 T3 PL2581387 T3 PL 2581387T3
Authority
PL
Poland
Prior art keywords
monoclonal antibody
tat hiv
tat
hiv
monoclonal
Prior art date
Application number
PL11306314T
Other languages
English (en)
Inventor
Erwann Loret
Gilbert Baillat
Sonia Mediouni
Jennifer Daniele Watkins
Michel Pierres
Original Assignee
Univ Aix Marseille
Inst Nat Sante Rech Med
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Aix Marseille, Inst Nat Sante Rech Med, Centre Nat Rech Scient filed Critical Univ Aix Marseille
Publication of PL2581387T3 publication Critical patent/PL2581387T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11306314T 2011-10-11 2011-10-11 Przeciwciało monoklonalne anty-Tat HIV-1 PL2581387T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11306314.3A EP2581387B1 (en) 2011-10-11 2011-10-11 An anti-HIV-1 Tat monoclonal antibody

Publications (1)

Publication Number Publication Date
PL2581387T3 true PL2581387T3 (pl) 2016-04-29

Family

ID=44862864

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11306314T PL2581387T3 (pl) 2011-10-11 2011-10-11 Przeciwciało monoklonalne anty-Tat HIV-1

Country Status (6)

Country Link
EP (1) EP2581387B1 (pl)
DK (1) DK2581387T3 (pl)
ES (1) ES2553597T3 (pl)
HU (1) HUE026344T2 (pl)
PL (1) PL2581387T3 (pl)
PT (1) PT2581387E (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3077417A1 (en) 2013-12-08 2016-10-12 Peptcell Limited Hiv antigens and antibodies and compositions, methods and uses thereof
WO2021159024A1 (en) * 2020-02-05 2021-08-12 Larimar Therapeutics, Inc. Tat peptide binding proteins and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5660827A (en) 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2597373A1 (en) * 2005-02-15 2006-08-24 Thymon, L.L.C. Methods and compositions for impairing multiplication of hiv-1

Also Published As

Publication number Publication date
EP2581387A1 (en) 2013-04-17
EP2581387B1 (en) 2015-09-16
HUE026344T2 (en) 2016-05-30
DK2581387T3 (en) 2015-12-07
PT2581387E (pt) 2015-12-30
ES2553597T3 (es) 2015-12-10

Similar Documents

Publication Publication Date Title
HUS2300021I1 (hu) Anti-IL-36R antitestek
PL3219729T3 (pl) Przeciwciało monoklonalne przeciwko IL-31
LT3378535T (lt) Humanizuoti antikūnai, atpažįstantys alfa-sinukleiną
DK2847231T3 (da) Multispecifikke monoklonale antistoffer
EP3427721C0 (en) HIGH CONCENTRATION MONOCLONAL ANTIBODY FORMULATIONS
CO6811812A2 (es) Anticuerpo anti-b7-h3
BR112013032552A2 (pt) variantes de anticorpos monoclonais humanizados imunomoduladores
HUE036663T2 (hu) Készítmény anti-alfa4béta7 antitesthez
HUE036664T2 (hu) Készítmény anti-alfa4béta7 antitesthez
CR20140127A (es) Anticuerpo anti-abtcr
DK2521736T3 (da) Humaniserede antistoffer
PL3088421T3 (pl) Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej
IL229618B (en) Isolated antibody that binds fcrn
EP2463368A4 (en) HUMANIZED ANTIBODIES AGAINST AMYLOID B OLIGOMERS
CO6841994A2 (es) Anticuerpos
PL2581387T3 (pl) Przeciwciało monoklonalne anty-Tat HIV-1